PARENT SESSION
1:30 PM to 3:30 PM
Sunday, April 21, 2002
Poster Session 8 Radiosensitizers and Bioreductive Drugs
Room: Nevada Exhibition Center
(P13-121) The effect of BBR3464 on colon cancer cells.
Hess, Suzanne*,1, Butler, Jerome1, Anderson, Joel1, Blackstock, A. William1, 1 Department of Radiation Oncology, Winston-Salem, NC
ABSTRACT-
Platinum drugs have been used to treat a variety of cancers with limited success due to either intrinsic tumor resistance or acquired resistance that often develops during the course of treatment. We are interested in testing novel platinum-based drugs that have a different binding profile compared to the traditional intra-strand cross-linking agents cisplatin, carboplatin, or oxaliplatin. We are studying BBR3464, a novel tri-platinated compound. BBR3464 induces both intra and inter-strand DNA cross-links. We have investigated the in vitro cytotoxic activity of BBR3464 in RKO and HT-29 colon cancer cells. Using clonogenic survival assays, we have observed a dose dependent cytotoxic effect with BBR3464. In addition, we have also observed a time dependent effect. Similar results were also observed with glioblastoma cells. Because platinum based drugs have been shown to act as radiation sensitizing agents, we are currently determining the radiation sensitization effect of BBR3464. Preliminary results suggest that time of irradiation following drug exposure may be crucial.
KEYWORDS: radiosensitizer, platinum , colon cancer